A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...
AllAfrica on MSN16h
South Africa: Excitement Builds for Long-Acting TB Treatments, but Research Still At Early StageBoth TB treatment and TB preventive therapy involve taking lots of pills, usually for several months. Researchers are working ...
allAfrica.com on MSN4d
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major ConferenceA single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...
A main obstacle to an HIV cure is that viral DNA integrates into the chromosomes of memory T cells (blue), which evade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback